Emelie Strandberg1, Karianne Vassbakk-Svindland1, Anna Henriksson1, Birgitta Johansson1,2, Olav Vikmoen3, David Kudrén2, Tim Schauer4, Henrik Lindman5, Fredrik Wärnberg6, Sveinung Berntsen1,7, Ingrid Demmelmaier1, Karin Nordin1, Truls Raastad3,7. 1. Department of Public Health and Caring Sciences. 2. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 3. Department of Physical Performance, Norwegian School of Sport Science, Oslo, Norway. 4. Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 5. Department of Oncology, Uppsala University Hospital, Uppsala. 6. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 7. Department of Sport Science and Physical Education, University of Agder, Kristiansand, Norway.
Abstract
INTRODUCTION: (Neo-)adjuvant chemotherapy for breast cancer has a deleterious impact on muscle tissue resulting in reduced cardiorespiratory fitness, skeletal muscle mass and function. Physical exercise during treatment may counteract some of these negative effects. However, the effects of resistance training (RT) alone have never been explored. The present study aims to investigate if heavy-load RT during (neo-)adjuvant chemotherapy counteracts deleterious effects on skeletal muscle in women diagnosed with breast cancer. We hypothesize that (neo-)adjuvant treatment with chemotherapy will reduce muscle fiber size, impair mitochondrial function, and increase indicators of cellular stress and that RT during treatment will counteract these negative effects. We also hypothesize that RT during (neo-)adjuvant chemotherapy will increase muscle and blood levels of potential antitumor myokines and reduce treatment-related side effects on muscle strength and cardiorespiratory fitness. METHODS: Fifty women recently diagnosed with breast cancer scheduled to start (neo-)adjuvant chemotherapy will be randomized to either randomized to either intervention group or to control group.The intervention group will perform supervised heavy-load RT twice a week over the course of chemotherapy (approximately 16-weeks) whereas the control group will be encouraged to continue with their usual activities. Muscle biopsies from m. vastus lateralis will be collected before the first cycle of chemotherapy (T0), after chemotherapy (T1), and 6 months later (T2) for assessment of muscle cellular outcomes. The primary outcome for this study is muscle fiber size. Secondary outcomes are: regulators of muscle fiber size and function, indicators of cellular stress and mitochondrial function, myokines with potential antitumor effects, muscle strength, and cardiorespiratory fitness. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Regional Ethical Review Board in Uppsala, Sweden (Dnr:2016/230/2). Results will be disseminated through presentations at scientific meetings, publications in peer-reviewed journals, social media, and patient organizations. TRIAL REGISTRATION NUMBER: NCT04586517.
INTRODUCTION: (Neo-)adjuvant chemotherapy for breast cancer has a deleterious impact on muscle tissue resulting in reduced cardiorespiratory fitness, skeletal muscle mass and function. Physical exercise during treatment may counteract some of these negative effects. However, the effects of resistance training (RT) alone have never been explored. The present study aims to investigate if heavy-load RT during (neo-)adjuvant chemotherapy counteracts deleterious effects on skeletal muscle in women diagnosed with breast cancer. We hypothesize that (neo-)adjuvant treatment with chemotherapy will reduce muscle fiber size, impair mitochondrial function, and increase indicators of cellular stress and that RT during treatment will counteract these negative effects. We also hypothesize that RT during (neo-)adjuvant chemotherapy will increase muscle and blood levels of potential antitumor myokines and reduce treatment-related side effects on muscle strength and cardiorespiratory fitness. METHODS: Fifty women recently diagnosed with breast cancer scheduled to start (neo-)adjuvant chemotherapy will be randomized to either randomized to either intervention group or to control group.The intervention group will perform supervised heavy-load RT twice a week over the course of chemotherapy (approximately 16-weeks) whereas the control group will be encouraged to continue with their usual activities. Muscle biopsies from m. vastus lateralis will be collected before the first cycle of chemotherapy (T0), after chemotherapy (T1), and 6 months later (T2) for assessment of muscle cellular outcomes. The primary outcome for this study is muscle fiber size. Secondary outcomes are: regulators of muscle fiber size and function, indicators of cellular stress and mitochondrial function, myokines with potential antitumor effects, muscle strength, and cardiorespiratory fitness. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Regional Ethical Review Board in Uppsala, Sweden (Dnr:2016/230/2). Results will be disseminated through presentations at scientific meetings, publications in peer-reviewed journals, social media, and patient organizations. TRIAL REGISTRATION NUMBER: NCT04586517.
Authors: Zaixing Shi; Andrew Rundle; Jeanine M Genkinger; Ying Kuen Cheung; Isaac J Ergas; Janise M Roh; Lawrence H Kushi; Marilyn L Kwan; Heather Greenlee Journal: J Cancer Surviv Date: 2020-03-04 Impact factor: 4.442
Authors: S Casla; P Hojman; I Márquez-Rodas; S López-Tarruella; Y Jerez; R Barakat; M Martín Journal: Clin Transl Oncol Date: 2014-06-04 Impact factor: 3.405
Authors: Lee W Jones; Kerry S Courneya; John R Mackey; Hyman B Muss; Edith N Pituskin; Jessica M Scott; Whitney E Hornsby; April D Coan; James E Herndon; Pamela S Douglas; Mark Haykowsky Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: I-Min Lee; Eric J Shiroma; Felipe Lobelo; Pekka Puska; Steven N Blair; Peter T Katzmarzyk Journal: Lancet Date: 2012-07-21 Impact factor: 79.321
Authors: J F Christensen; L W Jones; A Tolver; L W Jørgensen; J L Andersen; L Adamsen; P Højman; R H Nielsen; M Rørth; G Daugaard Journal: Br J Cancer Date: 2014-05-27 Impact factor: 7.640
Authors: Sara Mijwel; Malin Backman; Kate A Bolam; Anna Jervaeus; Carl Johan Sundberg; Sara Margolin; Maria Browall; Helene Rundqvist; Yvonne Wengström Journal: Breast Cancer Res Treat Date: 2017-11-14 Impact factor: 4.872
Authors: Blas A Guigni; Damien M Callahan; Timothy W Tourville; Mark S Miller; Brad Fiske; Thomas Voigt; Bethany Korwin-Mihavics; Vikas Anathy; Kim Dittus; Michael J Toth Journal: Am J Physiol Cell Physiol Date: 2018-09-12 Impact factor: 4.249
Authors: David Kiesl; Marina Kuzdas-Sallaberger; David Fuchs; Silvana Brunner; Romana Kommenda; Clemens Tischler; Herwig Hornich; Kaveh Akbari; Jörg Kellermair; Hermann Blessberger; Helmuth Ocenasek; Peter Hofmann; Philipp Zimmer; Milan R Vosko Journal: Front Neurol Date: 2022-03-25 Impact factor: 4.003
Authors: Maria Elena Garcia-Roca; Miguel Rodriguez-Arrastia; Carmen Ropero-Padilla; Carlos Hernando Domingo; Ana Folch-Ayora; Maria Dolores Temprado-Albalat; Ana Boldo-Roda; Eladio Collado-Boira Journal: J Pers Med Date: 2022-02-26